Re: Additional Reports of Exempt Distribution

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

jbuffett62

Rank: Treasurer [?]

Points: 480 [?]

Votes: 13 Score: 2.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Additional Reports of Exempt Distribution

in response to

Re: Additional Reports of Exempt Distribution

Nextblockbuster

posted on Jul 25, 2023 07:31AM

I believe Don said that if we hit ORR of 40 that we could immediately file to go to market? I think that was a year ago?

2 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply